Pharmacoeconomic review report. Tocilizumab (Actemra) (Hoffman-La Roche Limited).
Tocilizumab (Actemra, TCZ) is an IL-6 receptor agonist indicated for the treatment of giant cell arteritis (GCA) in adult patients. The recommended dose is 162 mg administered via subcutaneous injection weekly for two years plus 26 weeks of prednisone tapering. It is supplied as a solution for injec...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534095/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
